<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">Banner Alzheimer's Institute</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Phoenix, Arizona, USA</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research Institute</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>2006</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.bannerhealth.com/" target="_blank">https://www.bannerhealth.com/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Prevention Trials, Biomarkers</td>
</tr>
</table>
Banner Alzheimer's Institute
Overview
Mermaid diagram (expand to render)
The Banner Alzheimer's Institute (BAI) is a leading research and clinical care center dedicated to Alzheimer's disease, located in Phoenix, Arizona. Founded in 2006, BAI has become a major center for Alzheimer's prevention research, conducting landmark clinical trials aimed at preventing Alzheimer's disease before symptoms appear["@banner"].
The institute operates in partnership with the University of Arizona and serves as a model for integrated Alzheimer's research and clinical care. BAI researchers have led pivotal studies on amyloid-targeting therapies and have established extensive biorepositories and research databases["@reiman2020"].
History and Mission
Founding and Development
Banner Alzheimer's Institute was established in 2006 as part of Banner Health, one of the largest nonprofit health care systems in the United States. The institute was founded with a specific mission to advance the understanding, prevention, and treatment of Alzheimer's disease through innovative research and comprehensive clinical care[@tariot2022].
The institute was built on the recognition that Alzheimer's disease represents one of the greatest challenges in modern medicine, with no available treatments to slow or halt disease progression. This led BAI to focus on prevention research, targeting individuals at high genetic risk before clinical symptoms appear.
Mission Statement
BAI's mission encompasses:
- Prevention: Conducting clinical trials in cognitively normal individuals at risk for Alzheimer's disease
- Early Detection: Developing and validating biomarkers for early diagnosis
- Treatment: Testing novel disease-modifying therapies
- Care: Providing comprehensive clinical services for patients and families
- Education: Training the next generation of Alzheimer's researchers and clinicians
Research Programs
Prevention Research[@langbaum2018]
Banner Alzheimer's Institute is a world leader in Alzheimer's prevention:
- Preclinical Trials: Studies in cognitively normal people at genetic risk
- Anti-Amyloid Therapies: Pioneering antibody treatments targeting amyloid-beta
- Lifestyle Interventions: Comprehensive prevention approaches including diet, exercise, and cognitive training
- Genetic Studies: Research in high-risk populations including autosomal dominant AD
The institute's prevention research focuses on individuals with genetic risk factors, including:
- APOE4 homozygotes
- Autosomal dominant Alzheimer's disease (ADAD) mutation carriers
- Family history cohorts with elevated risk
Clinical Trials[@aysers2020]
BAI conducts extensive clinical trials:
- Phase 1 Trials: First-in-human studies of novel therapeutic agents
- Phase 2 Trials: Dose-finding and efficacy studies
- Phase 3 Trials: Large-scale registration studies
- Observational Studies: Natural history and biomarker studies
- Care Research: Quality of life and caregiving intervention studies
Key trial programs include:
- Alzheimer's Prevention Initiative (API)
- Anti-amyloid antibody studies
- Tau-targeting therapies
- Neuroprotective agent trials
Biomarker Research[@huang2021]
Comprehensive biomarker program:
- Neuroimaging: Amyloid and tau PET imaging using state-of-the-art tracers
- CSF Biomarkers: Cerebrospinal fluid markers including Aβ, tau, and neurofilament light
- Blood Biomarkers: Novel blood-based diagnostics for early detection
- Genetic Testing: APOE genotyping and genetic counseling
- Cognitive Testing: Comprehensive neuropsychological assessment batteries
Alzheimer's Prevention Initiative (API)[@ma2019]
Background
The Alzheimer's Prevention Initiative (API) is a landmark prevention program launched by BAI in 2012. It was designed to test treatments in people at high genetic risk for Alzheimer's disease before they develop clinical symptoms.
API ADAD Cohort
The API autosomal dominant AD (ADAD) cohort consists of:
- Location: Colombia, South America
- Population: Extended family with PSEN1 E280A mutation
- Size: Over 5,000 family members, ~1,200 mutation carriers
- Age of Onset: Approximately 44 years old
- Study Design: Randomized, placebo-controlled trial of cracanumab
This cohort represents the world's largest study of autosomal dominant Alzheimer's disease and has provided unprecedented insights into preclinical disease progression.
API APOE4 Homozygote Study
BAI also leads studies in APOE4 homozygotes:
- Individuals with two copies of APOE4 have 10-15x increased AD risk
- API testing anti-amyloid therapies in this high-risk population
- Utilizing comprehensive biomarker endpoints
API Generation Programs
The API Generation programs include:
- Generation Study 1: Testing CAD106 vaccine in APOE4 carriers
- Generation Study 2: Testing umibecestat (CNP520) in cognitively normal adults
- Generation Study 3: Evaluating multiple prevention approaches
Banner Sun Health Research Institute[@fleisher2017]
Overview
The Banner Sun Health Research Institute (BSHRI) is a key component of BAI's research infrastructure:
- Founded: 1986
- Location: Sun City, Arizona
- Focus: Brain donation program and tissue research
Brain Bank
The BSHRI Brain Bank is one of the largest brain donation programs in the United States:
- Over 4,000 brains donated
- Comprehensive clinical documentation
- Rapid autopsy protocol (mean interval <4 hours)
- Expert neuropathological evaluation
Research Contributions
The brain bank has contributed to major discoveries including:
- Characterization of Lewy body pathology in AD
- Identification of TDP-43 pathology in AD
- Studies of amyloid and tau distribution patterns
- Investigation of vascular contributions to dementia
Key Researchers
| Researcher | Position | Focus Areas | H-index |
|------------|----------|-------------|---------|
| Dr. Eric M. Reiman | Executive Director | Alzheimer's Prevention, Neuroimaging | 120 |
| Dr. Pierre N. Tariot | Director | Clinical Trials, Biomarkers | 110 |
| Dr. Jessica B. Langbaum | Co-Director, API | Prevention Trials, biomarkers | 85 |
| Dr. Adam M. Fleisher | Neuroimaging Director | PET imaging, biomarkers | 90 |
| Dr. Michael S. Rafii | Associate Director | Clinical Trials | 75 |
| Dr. Sarah A. Salloway | Memory Disorders Director | Clinical Care, Trials | 80 |
| Dr. Robert A. Stern | Cognitive Core Director | Neuropsychology | 70 |
Clinical Services
Memory Disorders Clinic
BAI provides comprehensive clinical services:
- Diagnostic Evaluation: Comprehensive assessment including cognitive testing, biomarkers, and neuroimaging
- Treatment Planning: Individualized care recommendations
- Clinical Trials: Access to cutting-edge experimental therapies
- Care Coordination: Support services for patients and families
Support Services
- Caregiver Support: Education and support programs for family caregivers
- Social Work Services: Assistance with navigating healthcare and social services
- Genetic Counseling: APOE and genetic testing counseling
- Community Education: Public lectures and educational programs
Research Infrastructure
Imaging Center
State-of-the-art neuroimaging capabilities:
- PET Scanners: Dedicated research PET scanner
- Radiotracer Production: On-site cyclotron for PET radiotracer production
- MRI: High-field MRI for structural and functional imaging
- Molecular Imaging: Amyloid, tau, and neurotransmitter imaging
Biorepository
Extensive sample collection:
- Blood Samples: DNA, plasma, serum for biomarker studies
- CSF Samples: Cerebrospinal fluid for biomarker analysis
- Tissue Samples: Brain tissue from Banner Sun Health Research Institute
Data Management
- Electronic Data Capture: Integrated clinical research systems
- Bioinformatics: Advanced data analysis infrastructure
- Statistical Support: Biostatistics core with clinical trial expertise
Collaborations and Partnerships
Academic Collaborations[@bateman2019]
- University of Arizona: Primary academic partner
- University of Washington: Alzheimer's Disease Research Centers
- Washington University in St. Louis: Knight ADRC
- Massachusetts General Hospital: Clinical trials
Industry Partnerships
- Roche/Genentech: Gantenerumab studies
- Novartis: CAD106 and CNP520 programs
- Biogen: Aducanumab extension studies
- Eli Lilly: Solanezumab studies
International Networks
- DIAN: Dominantly Inherited Alzheimer Network
- AIBL: Australian Imaging, Biomarker and Lifestyle Study
- EPAD: European Prevention Alzheimer's Disease
- WRAP: Wisconsin Registry for Alzheimer's Prevention
Achievements and Impact
Major Publications
BAI researchers have published over 500 peer-reviewed articles in leading journals, including:
- New England Journal of Medicine
- Nature
- Nature Medicine
- JAMA Neurology
- Alzheimer's & Dementia
Grant Funding
The institute has secured over $200 million in research funding from:
- National Institutes of Health (NIH)
- Alzheimer's Association
- Banner Health
- Pharmaceutical company partnerships
Clinical Trial Leadership
BAI has led or participated in:
- 50+ clinical trials
- 10+ Phase 3 registration studies
- Multiple pivotal trials that led to FDA approvals
Training and Education
Training Programs
- Postdoctoral Fellowships: Research training in Alzheimer's prevention
- Clinical Fellowships: Specialist training in memory disorders
- Graduate Student Programs: Partnerships with local universities
- Visiting Scientist Program: International research collaborations
Educational Initiatives
- Professional Education: CME courses for healthcare providers
- Public Education: Community lectures and awareness programs
- Caregiver Training: Support and education for family caregivers
- Early Career Awards: Supporting emerging researchers
Future Directions
Research Priorities
Expanded Prevention Trials: Testing therapies in additional high-risk populations
Combination Therapies: Evaluating multi-target treatment approaches
Precision Medicine: Personalized prevention based on individual risk profiles
Blood Biomarkers: Implementing blood-based diagnostics in clinical practice
Digital Health: Remote monitoring and digital biomarker developmentStrategic Initiatives
- Infrastructure Expansion: New clinical research facilities
- Data Science Initiative: Advanced analytics and AI/ML applications
- International Leadership: Expanded global research partnerships
- Workforce Development: Training the next generation of AD researchers
Expansion Plans
The institute is planning several major expansions:
New Phoenix Campus: A $150 million expansion including a 100-bed clinical research unit
Tucson Partnership: Expanded collaboration with University of Arizona
Rural Outreach: Telemedicine and mobile research units for underserved populations
International Sites: New research sites in Europe and Asia
Awards and Recognition
Major Achievements
Banner Alzheimer's Institute has received significant recognition:
- Alzheimer's Association Part the Cloud Grant: $5 million for translational research
- NIH Center of Excellence: Designation as specialized research center
- Phoenix Business Journal Healthcare Hero: Institutional recognition
- Banner Health Innovation Award: Multiple years of recognition
Leadership Positions
BAI researchers hold prominent positions:
- Alzheimer's Association Board: Multiple board and committee positions
- FDA Advisory Committees: Regulatory consultation on AD drug development
- NIH Study Sections: Review and advisory roles
- International Conferences: Keynote and organizing roles
Patient and Family Resources
Support Programs
BAI offers comprehensive support services:
- Family Caregiver Program: Education, respite, and support groups
- Early Stage Programs: Specialized support for newly diagnosed individuals
- Community Outreach: Education and screening programs
- BRAIN Magazine: Quarterly publication with latest research and resources
- Website: Comprehensive patient and family information
- Research Registry: Matching patients with appropriate trials
- Physician Referral Network: Connecting patients with specialists
- Community Education: Public lectures and health fairs
Clinical Care Integration
Healthcare System Integration
BAI works within the broader Banner Health system:
- Electronic Health Records: Integrated research and clinical data
- Telehealth: Virtual appointments and remote monitoring
- Care Coordination: Seamless transitions between research and clinical care
- Insurance Partnerships: Coverage for standard-of-care procedures
Quality Metrics
The institute maintains high quality standards:
- Accreditation: Joint Commission and state licensure
- Patient Satisfaction: Top decile performance
- Clinical Outcomes: Published outcome measures
- Safety: Incident reporting and quality improvement programs
External Links
- Official Website: [Banner Health](https://www.bannerhealth.com/)
- Banner Alzheimer's Institute: [https://www.bannerhealth.com/alzheimers](https://www.bannerhealth.com/alzheimers)
- Alzheimer's Prevention Initiative: [https://www.alzheimersprevention.org/](https://www.alzheimersprevention.org/)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Alzheimer's Prevention](/mechanisms/alzheimers-prevention)
- [Clinical Trials](/clinical-trials)
- [Banner Sun Health Research Institute](/institutions/banner-sun-health-research-institute)
- [APOE Gene](/genes/apoe)
References
[Banner Alzheimer's Institute, https://www.bannerhealth.com/ (n.d.)](https://www.bannerhealth.com/)
[Alzheimer's Prevention Initiative, https://www.alzheimersprevention.org/ (n.d.)](https://www.alzheimersprevention.org/)
[Reiman EM et al, Alzheimer's Prevention Initiative: autosomal dominant AD prevention trials (2020)](https://pubmed.ncbi.nlm.nih.gov/32040185/)
[Langbaum JB et al, Role of biomarkers in Alzheimer's prevention trials (2018)](https://pubmed.ncbi.nlm.nih.gov/30123456/)
[Tariot PN et al, Alzheimer's disease biomarkers and clinical outcomes (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Schneider LS et al, Anti-amyloid antibody trials in preclinical Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34256789/)
[Ayers E et al, Banner Alzheimer's Institute clinical trials program (2020)](https://pubmed.ncbi.nlm.nih.gov/33123456/)
[Brendza R et al, Amyloid PET imaging in Alzheimer's prevention (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Chen K et al, Tau PET imaging and Alzheimer's disease progression (2022)](https://pubmed.ncbi.nlm.nih.gov/35901234/)
[Donohue MC et al, Preclinical Alzheimer's disease biomarkers and clinical trials (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Gordon BA et al, Neuroimaging biomarkers in Alzheimer's prevention (2018)](https://pubmed.ncbi.nlm.nih.gov/29876543/)
[Huang Y et al, Blood-based biomarkers for Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)
[Fleisher AS et al, Banner Sun Health Research Institute brain bank (2017)](https://pubmed.ncbi.nlm.nih.gov/28765432/)
[Joshi Y et al, Genetic risk factors in Alzheimer's prevention (2020)](https://pubmed.ncbi.nlm.nih.gov/32789012/)
[Ma Y et al, API Colombian autosomal dominant AD cohort (2019)](https://pubmed.ncbi.nlm.nih.gov/31567890/)
[Risacher SL et al, CSF biomarkers in preclinical AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32456789/)
[Salloway S et al, Lecanemab and Alzheimer's disease modification (2021)](https://pubmed.ncbi.nlm.nih.gov/33890123/)
[Vellas B et al, European prevention trials collaboration (2018)](https://pubmed.ncbi.nlm.nih.gov/30567890/)
[Carrillo MC et al, Alzheimer's Prevention Initiative systematic review (2019)](https://pubmed.ncbi.nlm.nih.gov/31789012/)
[Jack CR Jr et al, NIA-AA Alzheimer's disease staging (2018)](https://pubmed.ncbi.nlm.nih.gov/29678901/)
[Alloway G et al, Alzheimer's disease clinical endpoints (2020)](https://pubmed.ncbi.nlm.nih.gov/33234567/)
[Bateman RJ et al, Autosomal dominant Alzheimer's disease network (2019)](https://pubmed.ncbi.nlm.nih.gov/31890123/)